A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice (FIRE)

October 5, 2022 updated by: Janssen-Cilag Ltd.

A Retro-Prospective Observational Study of Ibrutinib Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice

The purpose of this study is to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy for chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

508

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Paris Cedex 13, France

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Study population include chronic lymphocytic leukemia (CLL) or mantle-cell lymphoma (MCL) participants who were or will be treated by ibrutinib per routine clinical care on or after 21 November 2014.

Description

Inclusion Criteria:

  • Has a confirmed diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle-cell lymphoma (MCL), and is initiating ibrutinib therapy or has initiated ibrutinib therapy on or after 21 November 2014 (date of ibrutinib commercialization) for:

    1. treatment of CLL/SLL in participants who have received at least 1 prior therapy; or
    2. treatment in first line CLL/SLL participants in the presence of deletion (del) 17p or TP53 mutation in participants unsuitable for chemo-immunotherapy; or
    3. treatment of participants with relapsed or refractory MCL
  • Not currently participating in another investigational study, clinical study, or any expanded access program at study entry
  • Has not participated in the ibrutinib Autorisation Temporaire d'Utilisation (ATU) program
  • Participant must sign a written informed consent form (ICF) allowing data collection and source data verification

Exclusion Criteria:

  • Currently participating in another investigational study, clinical study, or any expanded access program at study entry
  • Participated in the ibrutinib Autorisation Temporaire d'Utilisation (ATU) program

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Cohort 1: Chronic Lymphocytic Leukemia (CLL) Participants
Participants with confirmed diagnosis of CLL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 1. The primary data source for this observational study will be the medical records of each enrolled participant.
Drug: Ibrutinib
Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib in routine clinical practice settings will be observed for 5 years.
Cohort 2: Mantle-Cell Lymphoma (MCL) Participants
Participants with confirmed diagnosis of MCL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 2. The primary data source for this observational study will be the medical records of each enrolled participant.
Drug: Ibrutinib
Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib in routine clinical practice settings will be observed for 5 years.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progressive-Free Survival (PFS)
Time Frame: Approximately up to 5 years
PFS in Chronic Lymphocytic Leukemia (CLL) and Mantle-Cell Lymphoma (MCL) participants will be determined. PFS is defined as the time from start of ibrutinib therapy to Progressive Disease (PD) or death from any cause. PD is defined as any new lesions or increase by greater than or equal to (>=) 50 percent (%) of previously involved sites from nadir.
Approximately up to 5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Response Rate (ORR)
Time Frame: Approximately up to 5 years
ORR observed in CLL and MCL participants will be reported. ORR is defined as the proportion of participants with at least an objective response (that is, complete response or partial response, or partial response with lymphocytosis for CLL participants) as assessed by the participating physician.
Approximately up to 5 years
Time to First Response
Time Frame: Approximately up to 5 years
Time to First Response in CLL and MCL participants will be reported. Time to first response is defined as the time from start of ibrutinib therapy until first objective response.
Approximately up to 5 years
Time to Best Response
Time Frame: Approximately up to 5 years
Time to best response in CLL and MCL participants will be reported. Time to best response is defined as the time from start of ibrutinib therapy until best objective response.
Approximately up to 5 years
Duration of Response
Time Frame: Approximately up to 5 years
Duration of response in CLL and MCL participants will be reported. Duration of response is defined as the time from start of ibrutinib therapy until PD or death resulting from progression. PD is defined as any new lesions or increase by >=50% of previously involved sites from nadir.
Approximately up to 5 years
Overall survival (OS)
Time Frame: Approximately up to 5 years
Overall survival in CLL and MCL participants will be reported. Overall survival will be measured from start of ibrutinib therapy to the date of death (all-cause mortality); and from diagnosis to the date of death.
Approximately up to 5 years
Duration of Ibrutinib Therapy
Time Frame: Approximately up to 5 years
Duration of ibrutinib therapy in CLL and MCL participants will be reported.
Approximately up to 5 years
Duration of a Treatment-Free Period
Time Frame: Every 6 months (Approximately up to 5 years)
Duration of treatment-free period in CLL and MCL participants will be reported.
Every 6 months (Approximately up to 5 years)
Duration of the First Non-Ibrutinib Subsequent Therapy Period
Time Frame: Approximately up to 5 years
Duration of the first non-ibrutinib subsequent therapy period in CLL and MCL participants will be reported.
Approximately up to 5 years
Participants' Daily Dose
Time Frame: Approximately up to 5 years
Daily dose of ibrutinib taken by CLL and MCL participants will be analyzed.
Approximately up to 5 years
Number of Participants Who Require Dose Modifications
Time Frame: Approximately up to 5 years
Number of CLL and MCL participants requiring dose modifications in the ibrutinib therapy will be reported.
Approximately up to 5 years
Number of Medications Added
Time Frame: Approximately up to 5 years
Number of medications added in the CLL and MCL treatment will be reported.
Approximately up to 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Janssen-Cilag Ltd.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 11, 2016

Primary Completion (Actual)

August 11, 2022

Study Completion (Actual)

August 11, 2022

Study Registration Dates

First Submitted

February 1, 2018

First Submitted That Met QC Criteria

February 1, 2018

First Posted (Actual)

February 7, 2018

Study Record Updates

Last Update Posted (Actual)

October 6, 2022

Last Update Submitted That Met QC Criteria

October 5, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CR107363
  • 54179060CAN4001 (Other Identifier: Janssen-Cilag Ltd.)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lymphoma, Mantle-Cell

Clinical Trials on Ibrutinib

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe